Diagnosis and Treatment of Mitochondrial Myopathies by Ahmed ST et al.
REVIEW
Diagnosis and Treatment of Mitochondrial Myopathies
Syeda T. Ahmed1 & Lyndsey Craven1 & Oliver M. Russell1 & Doug M. Turnbull1,2 & Amy E. Vincent1,2
# The Author(s) 2018
Abstract
Mitochondrial myopathies are progressive muscle conditions caused primarily by the impairment of oxidative phosphorylation
(OXPHOS) in the mitochondria. This causes a deficit in energy production in the form of adenosine triphosphate (ATP),
particularly in skeletal muscle. The diagnosis of mitochondrial myopathy is reliant on the combination of numerous techniques
including traditional histochemical, immunohistochemical, and biochemical testing combined with the fast-emerging molecular
genetic techniques, namely next-generation sequencing (NGS). This has allowed for the diagnosis to become more effective in
terms of determining causative or novel genes. However, there are currently no effective or disease-modifying treatments
available for the vast majority of patients with mitochondrial myopathies. Existing therapeutic options focus on the symptomatic
management of disease manifestations. An increasing number of clinical trials have investigated the therapeutic effects of various
vitamins, cofactors, and small molecules, though these trials have failed to show definitive outcomemeasures for clinical practice
thus far. In addition, new molecular strategies, specifically mtZFNs and mtTALENs, that cause beneficial heteroplasmic shifts in
cell lines harboring varying pathogenic mtDNA mutations offer hope for the future. Moreover, recent developments in the
reproductive options for patients with mitochondrial myopathies mean that for some families, the possibility of preventing
transmission of the mutation to the next generation is now possible.
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Mitochondrial Disease
Mitochondrial myopathies are an important group of progressive
muscle conditions, caused primarily by the impairment of oxida-
tive phosphorylation (OXPHOS). OXPHOS is the biochemical
process by which mitochondria produce energy in mammalian
cells in the form of adenosine triphosphate (ATP). Myopathy is
one of themost commonmanifestations of adult-onsetmitochon-
drial disorders due to the high cellular energy demand of skeletal
muscle. However, patients with mitochondrial myopathy often
have dysfunction in multiple organ systems resulting in variabil-
ity in clinical phenotype and prognosis [1].
Mitochondrial function is under the control of two ge-
nomes; the mitochondrial genome (mtDNA) and the nuclear
genome (nDNA); as such, mitochondrial myopathy can be
caused by pathogenic genetic variants in either of these ge-
nomes. This dual genetic control also means that mitochon-
drial disease is transmitted with the following inheritance pat-
terns: maternal (mtDNA), X-linked, autosomal recessive, au-
tosomal dominant. In addition, some relatively common mi-
tochondrial myopathies occur de novo.
The mitochondrial genome is a small, circular DNA mole-
cule that encodes 13 proteins of the OXPHOS machinery, 22
mitochondrial tRNA (mt-tRNA), and 2 mitochondrial rRNAs
(mt-rRNA). Primary mutations of the mtDNA include point
mutations affecting protein coding regions of the genome and
mt-tRNA genes which alter mitochondrial protein synthesis.
They also include single, large-scale mtDNA deletions which
can either be inherited or arise sporadically during embryo-
genesis [2]. The pathogenicity of mtDNA mutations is further
complicated by heteroplasmy (the state in which there is co-
existence of both mutant and wild-type mtDNA in a given
cell) and the threshold effect (when the proportion of mutant
mtDNA exceeds a given limit and causes a biochemical defect
in a cell) [3].
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The nDNA encodes 1171 known and 442 predicted mito-
chondrial proteins (MitoMiner v.Q2 2018 [4]), including
OXPHOS subunits, assembly factors for OXPHOS complexes
and proteins required for mtDNAmaintenance. Mutations in the
genes encoding the mtDNA maintenance machinery can lead to
either mtDNA depletion or multiple mtDNA deletions.
Clinical Features of Mitochondrial Myopathies
Patients with mitochondrial myopathies have diverse clinical
phenotypes (Fig. 1), some features may be similar to other my-
opathies and others are more specific for patients with mitochon-
drial disease. In virtually all patients with mitochondrial myopa-
thy, there is potential involvement of other systems which may
well be the prominent and life-threatening feature—for example,
cardiomyopathy, epilepsy, or stroke-like episodes (Fig. 1) [1].
Indeed the most frequent presentation of mitochondrial myopa-
thy is in combination with other symptoms which is often the
clue to likely mitochondrial involvement. While beyond the
scope of this review to cover these features, it is essential that
they are considered when evaluating all patients.
Chronic progressive external ophthalmoplegia (CPEO) is
a common presentation for patients with mitochondrial dis-
ease [5] and usually involves progressive ptosis and a slow
progressive ophthalmoplegia with or without double vision.
CPEO can occur either as an isolated symptom or as part of a
multisystem disease such as Kearns–Sayre syndrome and is
commonly associated with proximal myopathy.
Proximal myopathy is the most common form of myopathy
in mitochondrial disease patients. The degree of weakness is
variable and commonly fatigable. In some patients, this weak-
ness is progressive and can affect diaphragm and/or respirato-
ry muscles, eventually requiring ventilator support.
Exercise-induced muscle pain is a common feature, limit-
ing exercise tolerance. Rarely, this can be associated with
rhabdomyolysis, which should be included in the differential
diagnosis of mitochondrial myopathies.
Fatigue is the most commonly patient-reported symptom
[6]. Interestingly, in a survey of patients, Gorman et al. found
fatigue to be associated with exercise intolerance, difficulty
swallowing, cutting food and dressing, hygiene, gait, and psy-
chiatric symptoms but not with myopathy [6].
Diagnosis of Mitochondrial Myopathies
The diagnosis of mitochondrial myopathies involves a multi-
disciplinary approach. History and physical examination are
crucial for recognizing that mitochondrial myopathy is a poten-
tial diagnosis but also to suggest the most appropriate diagnos-
tic studies. The diagnostic investigations include histological
and immunohistochemical studies, enzymatic analysis of the
OXPHOS complexes, and the genetic analysis of the mtDNA.
Fig. 1 Mitochondrial disease symptoms and skeletal muscle biopsies.
Mitochondrial diseases are multisystemic disorders that present with a
wide variety of neurological, muscular, hepatic, and gastrointestinal
symptoms, among others (left). Myopathy is associated with
mitochondrial disease and often leads to exercise intolerance, cramps,
and fatigue. Skeletal muscle biopsies are commonly taken for
diagnostic purposes. When reacted for COX/SDH histochemistry, a
mosaic pattern of affected (COX-deficient) and unaffected (COX-
positive) muscle fibers can be seen in transverse sections (light blue).
When muscle biopsies are examined longitudinally, COX-deficiency
can be seen restricted to small segments along the length of the fiber
surrounded by COX-positive regions (orange)
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Additionally, if a nuclear genetic diagnosis is suspected, a
targeted nDNA sequencing approach may be used. If no path-
ogenic mutation is identified, whole genome and whole exome
screens are now commonly used to search for potential genetic
diagnoses, with new disease genes constantly being identified.
By integrating the information from these diagnostic tests, it
allows for a diagnosis in the majority of patients.
Muscle Biopsy
Skeletal muscle is commonly affected in mitochondrial dis-
ease and is the most frequently biopsied tissue, although the
increasing use of genetic tests is likely to reduce the need for
muscle biopsies in the future [7]. Patients with mitochondrial
myopathymay show histochemical alterations in their skeletal
muscle which indicate mitochondrial dysfunction, although in
some patients, the muscle biopsy can appear normal. These
mitochondrial abnormalities can be identified using several
routine histological and immunological studies.
One example detected in some patients is the staining of
skeletal muscle cryosections with the modified Gomori
Trichrome, highlighting the presence of ragged-red fibers
(RRF). These fibers can also be detected using succinate de-
hydrogenase (SDH, complex II) histochemistry, which detects
the mitochondrial aggregates in the subsarcolemmal region of
the fiber due to mitochondrial proliferation that occurs as a
result of mitochondrial OXPHOS dysfunction [8].
Another important diagnostic feature of mitochondrial myop-
athy is the presence of cytochrome c oxidase (COX, complex
IV)-negative fibers as detected by the sequential COX/SDH his-
tochemistry. Amosaic pattern is commonly observedwith COX-
negative fibers appearing blue, among the normal COX-positive
fibers which appear brown (Fig. 1). Furthermore, COX deficien-
cy is segmental along the length of the muscle fiber (Fig. 1). The
mosaic pattern is due to different levels of mutational
heteroplasmy with high mutation load leading to respiratory
chain deficiency [9, 10]. Mutation load is known to increase in
cells throughout life, a process termed clonal expansion, which
means that healthy aged individuals accumulate a low frequency
of COX-negative fibers [9, 11]. However, a suggestive diagnosis
of mitochondrial myopathy is only made when individuals har-
bor COX-negative fibers at a frequency of > 5%.
While COX/SDH fails to provide information on complex I
deficiency, a more recently established quadruple immunofluo-
rescent assay [13], has been shown to effectively identify isolat-
ed complex I downregulation in skeletal muscle biopsies of
patients for diagnostic purposes. These patients had a confirmed
genetic diagnosis in a nDNA-encoded subunits of complex I or
assembly factors, or mutations in the mtDNA complex I sub-
units, with some patients having mitochondrial myopathy [12,
13].
Other pathological features which may be seen in skeletal
muscle are nonspecific. These include neurogenic atrophy,
internal nuclei, abnormal variation in fiber size, and accumu-
lations of glycogen or lipid.
Biochemical Studies
Spectrophotometric evaluation of individual respiratory chain
complex activities is an important approach to the biochemical
investigation and diagnosis of mitochondrial myopathies. It can
be performed in either fresh or frozenmuscle homogenate; how-
ever, the latter is more common in diagnostic centers due to
cross-continental or national referral of patients. Each complex
can be analyzed in isolation following the oxidation/reduction of
specific substrates or substrate analogs. The spectrophotometric
enzyme assays are as follows: NADH:ubiquinone oxidoreduc-
tase for complex I, succinate:cytochrome c oxidase oxidoreduc-
tase for complex II, ubiquinol cytochrome c oxidoreductase for
complex III, cytochrome c oxidase for complex IV. The mea-
surement of complex V (oligomycin-sensitive ATP synthase) is
more challenging and requires the use of fresh material and is
often measured in cultured skin fibroblasts. Bernier et al. [14]
recommended 20–30% of normal complex activities as a crite-
rion for the diagnosis of mitochondrial myopathies. However, a
normal respiratory chain enzyme activity does not exclude the
diagnosis of mitochondrial myopathies as a small percentage of
respiratory chain deficiency cells may not be detectable by en-
zyme measurements on tissue homogenates.
Another biochemical study which proves to be a helpful
step in the diagnosis of mitochondrial myopathy is the blue
native acrylamide page (BN-PAGE) assay, which is used to
assess the relative abundance of fully assembled respiratory
chain enzyme complexes. Similar to the spectrophotometric
assay, deficiency of the complexes can be seen as an isolated
single complex or a combined deficiency.
Molecular Genetics Studies
While histochemical and biochemical studies pave the way for
appropriatemolecular genetic testing, the diagnostic procedure in
mitochondrial diseases has shifted towards the Bgenetic first
approach^ because of the advances made with next-generation
sequencing (NGS) [15]. The application of NGS techniques in-
cluding targeted multi-gene panels of candidate genes, unbiased
exome sequencing and whole genome sequencing, has revolu-
tionized the diagnostic approach, replacing the sequentialmethod
of sequencing candidate genes through Sanger sequencing as the
first diagnostic approach. The high-throughput analysis of many
genes has led to an increase in the pace of diagnosis and reducing
costs.Moreover, unlike Sanger sequencing, NGS can be used for
determination of mtDNA heteroplasmy and deletions, although
real-time PCR, pyrosequencing, and long-range PCR are still
commonly used. The identification of a causative molecular de-
fect facilitates a diagnosis of mitochondrial myopathy in the
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patient and family members, permitting disease management,
genetic counselling, and a variety of reproductive options.
Molecular Studies to Identify Causative Genes
Mutations causing mitochondrial myopathy can be found in
either the mtDNA or nDNA (Fig. 2). For mitochondrial disease
in general, pathogenic mutations have been reported in all 37
mtDNA genes and more than 254 nDNA-encoded genes [16].
A search of OMIM, ClinVar, and MitoMap yielded 31 mtDNA
genes and 29 nDNA genes that are associated with mitochon-
drial myopathy at time of writing. However, with new disease
genes being identified at a rapid rate, this is likely to be an
underestimate and the muscle is often involved in many of
the more systemic mitochondrial diseases.
When clinical history shows evidence of a maternally
inherited disorder, or a typical mitochondrial myopathy clinical
phenotype, the entire mitochondrial genome is typically ana-
lyzed. NGS allows for deep coverage across mtDNA and thus
detection of low levels of heteroplasmy, point mutations, and
breakpoints of single, large-scale mtDNA deletions. Analysis
can be undertaken from mtDNA extracted from blood, skin
biopsy, or muscle. However, possible mitotic segregation or
indeed a loss of mtDNA mutation from mitotic tissues [17]
means that if an mtDNA mutation is strongly suspected, then
analysis of muscle mtDNA is recommended.
When the compilation of various information from the clin-
ical history and histochemical and biochemical tests indicate
that the pathogenic mutation is located in the nDNA, whole
exome sequencing (WES), whole genome sequencing (WGS)
or a targeted multigene panel of candidate genes can be
employed to identify the causative gene using DNA extracted
from blood. Due to the large number of nuclear-encoded mito-
chondrial genes the benefits of NGS are obvious [18, 19].
In the case of novel mutations that have not been previous-
ly reported, functional tests must be undertaken to confirm the
pathogenicity of the defect. These typically include looking at
pathogenicity predictions based on protein structure and
Brescue^ experiments where patient cells are transfected with
a wild-type copy of the suspected gene and this is shown to
rescue the disease phenotype.
Additional Molecular Studies of mtDNA
For some patients with mitochondrial myopathy, it is helpful to
determine mtDNA copy number in muscle tissue using real-
time PCR. If the mtDNA content is depleted, it indicates that
the defect has occurred in a nuclear gene responsible for
mtDNA replication and/or maintenance of the deoxynucleotide
pools and thus may be helpful for targeted nuclear genetic test-
ing if not already completed [20].
Real-time PCR and long-range PCR may be used if a sin-
gle, large-scale mtDNA deletion or multiple mtDNA deletions
are suspected. Single, large-scale mtDNA deletions are most
reliably detected in muscle and through determining the size
of deletion and heteroplasmy provides important information
as regards to disease severity and progression [21]. In com-
parison, the presence of multiple mtDNA deletions indicates a
Fig. 2 Molecular genetics of
mitochondrial myopathy. A
search of OMIM, ClinVar, and
Mitomap from genes causing
mitochondrial myopathy yielded
60 genes. Of these, 31 are
mitochondrial genes, including 8
protein-encoding and 23 tRNA
mutations. The remaining 29
genes are encoded by the nucleus
and have a variety of functions,
including subunits and assembly
factors of the respiratory chain,
mtDNA replication and
maintenance, mitochondrial
shape, mitochondrial translation,
transport, proteases, lipid
metabolism, and iron sulphur (Fe-
S) cluster formation. Due to the
speed at which needed genes are
identified, this is likely to be an
underestimate of causative genes.
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genetic defect in a nuclear gene involved in mtDNA mainte-
nance and provides guidance for nDNA sequencing.
Other Investigations into Mitochondrial Myopathies
Lactate–Pyruvate Lactate is a product of anaerobic glucose me-
tabolism which accumulates when the metabolism is impaired,
causing a shift in the oxidized-to-reduced NAD+/NADH ratio
within the mitochondria—indicated by the blood lactate–pyru-
vate ratio. The determination of lactate concentrations at rest or
following exercise has become a diagnostic tool for mitochon-
drialmyopathy [22, 23]. However, many patients do present with
consistently normal lactate–pyruvate ratio especially in adults.
Fibroblast Growth Factor 21 Fibroblast growth factor 21 (FGF-
21), which has a regulatory role in lipid metabolism, can also be
used as a blood serum biomarker for mitochondrial diseases.
FGF-21 levels are seen to be raised in patients who have muscle
involvement, and thus, in cases with suspected mitochondrial
myopathies, the noninvasive measurement of the growth factor
acts as a helpful and sensitive first-line investigation in the diag-
nostic process [24, 25]. Furthermore, FGF-21 specificity for mi-
tochondrial disease has been determined to be above 90% [26].
Growth Differentiation Factor 15 More recently, the growth
differentiation factor 15 (GDF-15), which is a member of the
transforming growth factor β superfamily, is shown to be
significantly higher in the serum of patients with mitochondri-
al disease [27, 28]. The serum marker has been seen to be
associated with disease severity and so is deemed the most
useful biomarker for mitochondrial diseases [27].
Exercise Test The use of exercise testing, usually by bicycle or
treadmill, is used for research and as a clinical diagnostic test
for mitochondrial myopathy. Exercise intolerance during clin-
ical observation can be demonstrated through taking venous
blood sampling both during and after exercise. The test high-
lights a potential increase in concentration of muscle metabo-
lites (lactate and pyruvate) in venous blood supply (measured
as systemic arteriovenous oxygen (a-vO2)) during post-
exercise recovery and a slow clearance of the accumulated
plasma lactate. The aerobic forearm test is also used as a
screening tool for mitochondrial myopathy, coupled with the
venous oxygen saturation measurements. In a patient with
mitochondrial myopathy, the combined test will reveal a de-
crease in oxygen desaturation in the venous blood as mito-
chondrial dysfunction in skeletal muscle results in its inability
to extract oxygen from blood [29].
Treatment for Mitochondrial Myopathies
There are currently no effective or disease-modifying treat-
ments available for the majority of patients with mitochondrial
myopathies. Instead, existing therapeutic options focus on the
symptomatic management of disease manifestations, helping
to improve the patients’ quality of life. Disease management is
tailored to the individual patient according to their specific
needs and requires the input of many different healthcare pro-
fessionals such as neurologists, endocrinologists, cardiolo-
gists, dieticians, speech and language therapists, and physio-
therapists. Treatment guidelines are in place to help provide
for the management of patients in a clinical setting (for further
information, see the guidelines available at: http://www.
newcastle-mitochondria.com/clinical-professional-home-
page/clinical-publications/clinical-guidelines/).
An increasing number of clinical trials, usually designed
to be double blinded and placebo controlled, have investi-
gated the therapeutic effects of various vitamins, cofactors,
and nutritional supplements, though often these trials have
failed to show definitive beneficial primary and secondary
outcomes (referred to in this review). Moreover, new molec-
ular and cellular strategies are being proposed that act on a
molecular or cellular level, for example restriction endonu-
cleases technologies. Treatment options are described below
and both previous and ongoing clinical trials are summa-
rized in Table 1, and their molecular taregts detailed in
Fig. 3.
Ubiquinone and Ubiquinone Analog
CoQ10, an electron transport chain component involved in
shuttling electrons from complex I and complex II to complex
III via the quinone pool, has been shown to be an effective
treatment option in patients who harbor a rare congenital
CoQ10 deficiency [30]. The compound has been evaluated
in a phase 2 clinical trial which included adult patients with
either myoclonic epilepsy, lactic acidosis, and stroke-like ep-
isodes (MELAS), Leber’s hereditary optic neuropathy
(LHON), or CPEO. The study reported minor improvements
in the aerobic capacity and post-exercise lactate levels, but
there were no improvement in clinical measures such as
strength or resting lactate [31]. A phase 3 trial has also been
completed which aimed to show that oral CoQ10 was a safe
effective treatment for children with inherited mitochondrial
disease caused by defects in specific respiratory chain com-
plexes or mtDNA mutations (Clinical Trial identifier:
NCT00432744). No results have been reported as of yet [32].
Idebenone, a synthetic quinone analog of CoQ10, may
have the potential to restore cellular ATP generation [33]. It
also acts as an antioxidant by protecting the lipid membrane
and mitochondria from oxidative damage. Idebenone was
used in a randomized controlled trial (Clinical Trial identifier:
NCT00747487) which showed an improvement in secondary
outcome measures in LHON patients with discordant visual
acuities [34]. Following this, LHON became the first mito-
chondrial disease for which a treatment has been approved
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by the EuropeanMedicine Agency. Idebenone was also inves-
tigated in a phase 2 clinical trial (Clinical Trial identifier:
NCT00887562) at two different doses of either 900 mg or
2400 mg in MELAS patients [35, 36]. On the completion of
the trial, the results reached no statistical significance.
Targeting Mitochondrial Biogenesis
Nicotinamide riboside (NR), a form of vitamin B3 and a natural
precursor of NAD+, has been shown to be a promising treatment
strategy for mitochondrial myopathy. NR increases the levels of
Table 1 Treatment options for mitochondrial myopathies
Treatment Target of intervention Clinical Trial
identifier
Clinical
phase
Outcome
CoQ10 Increase respiratory chain flux,
serve as antioxidant
NCT00432744 Phase 3 Completed—no data available
Idebenone Serve as antioxidant NCT00887562 Phase 2 Primary endpoint did not reach a significant endpoint
at the completion of study
NCT00747487 Phase 2 Improvement in secondary outcome measures in patients
with LHON patients with discordant visual acuities
Nicotinamide
riboside (NR)
NCT03432871 N/A Recruiting—no data available.
Acipimox NCT00943059 2-week treatment, dose of 250 mg three times a day,
showed increase in skeletal muscle mitochondrial
oxidative capacity.
An improvement in the ATP production
Bezafibrate Mitochondrial biogenesis NCT02398201 Phase 2 Change in respiratory enzyme activity
RTA-408 NRF2 activator, NFĸB inhibitor,
antioxidant
NCT02255422 Phase 2 Completed—no data available
Exercise NCT00457314 Phase 2 N/A (status of study unknown)—no data available
MTP-131 Cardiolipin stabilization NCT02367014 Phase 1/2 Improved exercise intolerance and walking distance
in 6 min walk test
NCT02805790 Phase 2 Ongoing
NCT02976038 Phase 2 Ongoing
KH176 Antioxidant NCT02909400 Phase 2 Ongoing
Fig. 3 Routes to treatment.
Schematic depicts the
mitochondrial targets of
treatments currently being tested
for use in treating mitochondrial
myopathy. Awide range of
approaches are currently in use
including the targeting of
mitochondrial biogenesis
(bezafibrate, RTA-408, exercise,
acipimox and nicotinamide
riboside), oxidative
phosphorylation (CoQ10,
idebenone, riboflavin and
thiamine), ROS (RTA-498,
KH176, CoQ10, idebenone),
increasing NAD+ (acipimox and
nicotinamide riboside), mtDNA
gene editing (mitochondrial
TALENS and zinc finger
nucleases), lipid utilization
(ketogenic diet), and cardiolipin
stabilization (elamipretide)
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NAD+ which has been shown to induce mitochondrial biogene-
sis, thus increasing oxidative ATP production capacity [37, 38]. A
study by Khan et al. [39], investigated the effect of NR using
Deletor mice which have a mutation in the mtDNA Twinkle
(TWNK) helicase [40]. Multiple mtDNA deletions accumulate
in the skeletal muscle from these mice causing COX-negative
fibers and eventually myopathy after the age of 12 months. The
study administered NR at a dose of 400 mg/kg/day to all control,
presymptomatic, and postsymptomatic mice for a period of
4 months, a regime which had already proven to increase levels
of NAD+ in skeletal muscle of wild-type mice [37]. The findings
showed that NR prevented both the development and progression
of mitochondrial myopathy. The treatment also resulted in a sig-
nificant induction of mitochondrial biogenesis and oxidative me-
tabolism, similar to the findings of previous studies [37, 38]. The
increased biogenesis resulted in a delayed development of mor-
phological hallmarks, ultrastructural abnormalities, and the pre-
vention of mtDNA deletion accumulation in skeletal muscle. A
more recent clinical trial is underway investigating NR supple-
mentation in patients with mitochondrial disease to induce mito-
chondrial biogenesis (Clinical Trial identifier: NCT03432871) but
results are yet to be confirmed at the completion of the trial.
Further research is also underway to improve the uptake of NR
into patient blood stream by providing patients with a potential
modified release oral supplement or intravenous version of NR.
A NAD+ precursor compound named acipimox has also
been tested in an interventional clinical trial studywhich recruit-
ed patients with type 2 diabetes mellitus (Clinical Trial identi-
fier: NCT00943059). Findings from the trial showed that a 2-
week treatment with 250 mg of acipimox three times daily
resulted in an increase in skeletal muscle mitochondrial oxida-
tive capacity and an improvement in the ATP production.
Though the researchers believe further insight need to be given
into the safety and efficacy of the compound as a potential
treatment option [41]. An upcoming trial for acipimox is soon
to start in Newcastle, UK.
Bezafibrate is a pan-PPAR agonist that stimulates PGC1α, a
coactivator responsible for the induction of mitochondrial bio-
genesis through its interaction with a number of transcription
factors. Preclinical studies undertaken on various mouse models
have reported varied findings as to whether bezafibrate could be
a potential therapeutic strategy for mitochondrial myopathies.
One study on Deletor mice showed that bezafibrate treatment,
starting at the time of disease manifestation (12 months of age),
resulted in amilder progression of myopathy and reduced COX-
negative fibers and mtDNA deletions in skeletal muscle [42]. In
contrast, studies using the Surf1-KO mice (a model of early-
onset partial COX-deficiency) and the COX15−/− mice showed
no change in COX-activity, percentage COX-deficient fibers,
and, importantly, no induction of mitochondrial biogenesis.
Rather, the studies showed a suppression with no increase in
the PPARs or PGC1α expression following treatment [42, 43].
However, both studies did highlight the adverse effects of the
drug on mice, mainly severe lipid metabolism side effects and
hepatomegaly. Despite these findings, two clinical trials are cur-
rently ongoing for bezafibrate treatment. The first is a random-
ized placebo-controlled trial aiming to assess the safety and
efficacy of bezafibrate in mitochondrial myopathy patients
(EudraCT number: 2012-002692-34). The trial is administrating
bezafibrate orally at a dose of 200 mg in patients aged 2 to
50 years. The second trial, which is a phase 2, open labelled
feasibility study is aiming to provide proof of the effects of
bezafibrate on six patients with the m.3243A >G mutation
(Clinical Trial number: NCT02398201). The results of these
clinical trials are not yet published.
RTA-408 is a synthetic triterpenoid compound and a potent
activator of nuclear factor erythroid 2-related factor 2 (Nrf2),
working to increase the cellular antioxidant response [44].
Nrf2 is a transcriptional target of PGC1α and Nrf2 which
promotes mitochondrial biogenesis [45]. Therefore, RTA-
408 has the potential to improve muscle function, oxidative
phosphorylation, antioxidant capacity, and mitochondrial effi-
ciency in patients with mitochondrial myopathy. The drug
form of RTA-408 is called omaveloxolone which has been
investigated in a recently completed phase 2, clinical trial (in
a total of 53 patients with mitochondrial myopathy (Clinical
Trial number: NCT02255422—known as the MOTOR trial);
however, the results are not yet published.
Ketogenic diets, which consist of a low carbohydrate and
high lipid content which helps the lipid utilization by the mito-
chondria, have been proposed as a possible treatment for mito-
chondrial myopathies. The diet was found to simulate mito-
chondrial oxidative metabolism in Deletor mice, reducing the
amount of COX-negative fibers, preventing mitochondrial ul-
trastructural abnormalities in the skeletal muscle and inducing
mitochondrial biogenesis [46]. Another preclinical trial found
that a ketogenic culturemedium killed cybrid cell lines carrying
mtDNA mutation derived from a heteroplasmic patient with a
single, large-scale mtDNA deletion. A reduction in the mtDNA
deletion load was detected in the heteroplasmic cells line indic-
ative of a heteroplasmic shift [47]. Furthermore, Ahola et al.
[48] tested a ketogenic diet called the modified Atkins Diet
(mAD) in five patients with mitochondrial myopathy with ei-
ther single or multiple mtDNA deletions. Results of the pilot
study showed no induction of mitochondrial biogenesis. A 2-
year follow-up of the patients revealed an improvement in
muscle strength, showing a potential activation of muscle re-
generation. Despite the positive outcomes, further work is war-
ranted to determine whether ketogenic diets can have a thera-
peutic effect on patients with mitochondrial myopathy.
Targeting the Regulation of Lipid Dynamics
Elamipretide (previously Bendavia), is a member of the Szeto-
schiller (SS) family. The drug targets the mitochondrial inter-
membrane lipid cardiolipin [49], working to stabilize the lipid
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structure. Promising findings from preclinical trials have shown
that the compound led to an increase in the OXPHOS efficiency
through a reduction of ROS generation and so ultimately an
increase in ATP production [50, 51]. The drug has been
assessed in mitochondrial myopathy patients (Clinical Trial
identifier: NCT02367014, known as MMPOWER) and recent-
ly published data from the trial showed that patients had im-
proved exercise intolerance and walking distance after the ad-
ministration of the drug at the highest dose [52]. These findings
have led to an ongoing extension trial (Clinical Trial identifier:
NCT02976038, MMPOWER2).
Nutritional Supplementations
Another small molecule being investigated for treatment of mi-
tochondrial myopathy is KH176, a vitamin E derivative which
acts a potent ROS scavenger. An initial dose–dependent study
conducted by Koene et al. [53] showed that the molecule was
tolerated at a dose of 800 mg in male participants, causing
clinically relevant changes to cardiac electrophysiology tests.
A phase 2 clinical trial is currently being undertaken to investi-
gate this further (Clinical trial identifier: NCT02909400).
Exercise
It is well documented that exercise programs (either aerobic,
endurance, or resistance) can provide a safe therapeutic option
to patients with mitochondrial myopathy, benefiting the bio-
chemical (increasing phosphocreatine synthesis and mitochon-
drial enzymes) and clinical (work capacity, fatigue, quality of
life, and strength) end points [54–61].Exercise has been shown
to promote mitochondrial biogenesis through activation of
PGC1α, AMPK, P38 , MAPK, and RCG-1β. However, it is
not yet clear if exercise is having an effect on the underlying
pathogenesis of mitochondrial myopathy or reversing the
deconditioning of the muscle. A phase 2 exercise trial consisting
of 50 patients with mitochondrial myopathy is currently ongoing
(Clinical Trial identifier: NCT00457314) and results are yet to be
confirmed. It should, however, be remembered that the benefits
of exercise will be limited to those patients that are physically
able; thus, development of exercise-mimetic drugs is desirable.
Other Potential Treatment Options for Mitochondrial
Myopathies
The development of alternative strategies that act on amolecular
level to manipulate the mitochondrial genome is more recently
being proposed as therapeutic options for mitochondrial dis-
eases. This manipulation of mtDNA is achieved with the use
of restriction endonucleases, engineered specifically for the mi-
tochondria. The approaches are designed to recognize and bind
to specific mtDNA sequences, induce a double-strand break,
and initiate targeted degradation of the mutant mtDNA in a
heteroplasmic population. One such approach involves the use
of mitochondrially targeted zinc finger nucleases (mtZFN), a
heterodimer nuclease consisting of a DNA binding site (tandem
repeat of zinc fingers binding three bases each), and a DNA
cleavage domain (a Fok1 endonuclease). A further development
tomtZFN is mitochondrially targeted transcription activator like
effectors (TALE) fused with a Fok1 nuclease (together abbrevi-
ated to mtTALENs). Studies have shown the ability of both
mtZFNs and mtTALENs to selectively eliminate mutant
mtDNA in cell lines harboring a number of pathogenic muta-
tions, including the mtDNA point mutations m.8993T >G (as-
sociated with neuropathy, ataxia, and retinitis pigmentosa
(NARP)), m.8344A >G (associated with myoclonic epilepsy
with ragged-red fibers (MERRF)), m.13513A >G MT-ND5
mutation (associated with MELAS and Leigh syndrome (LS))
and also the Bcommon deletion^ m.8483-1345del4977 (associ-
ated with CPEO and Kearns–Sayre syndrome (KSS)). These
studies showed that through the targeted elimination of mutated
mtDNA, a beneficial shift in heteroplasmy and improvement in
the biochemical deficit can be achieved [62–67]. However, de-
spite the encouraging findings, these techniques are limited by
their lack of efficacy in the delivery mechanism to affected
tissues. Once this issue has been resolved, gene-editing tech-
niques could offer a potential treatment option for patients with
primary mutations in the mitochondrial genome.
Deoxypyramidine bypass therapy has been trialled in mi-
tochondrial depletion syndromes, such as those caused by a
mutation in thymidine kinase 2 (TK2). Garone et al. investi-
gated the effect of dCMP and dTMP supplementation in a
TK2 mouse model. This supplementation bypassed the TK2
defect, increasing dTTP levels, and ameliorated biochemical
abnormalities in these mice [68].
Reproductive Options
In addition to a wide variety of treatment options, reproductive
options are also available. Patients who have been diagnosedwith
a pathogenicmutation in either nDNAormtDNAknown to cause
mitochondrial disease have a number of reproductive options that
aim to reduce the risk of transmitting the disease to their offspring.
One option is oocyte or sperm donation (depending upon which
parent is affected) which can prevent the inheritance of mitochon-
drial disease. An important consideration for some, however, is
that the mother or father will not be genetically related to the
offspring. Therefore, an alternative is prenatal diagnosis and pre-
implantation genetic diagnosis (PGD). These options have been
used successfully to prevent transmission of nDNA and mtDNA
mutations associated with mitochondrial disease [69, 70]. For the
latter, the unique features of mtDNA mean that they will not be
suitable for women who are homoplasmic for an mtDNA muta-
tion or produce oocytes with high a mutation load.
The most recent reproductive option that may allow some
women to have a genetically related child while reducing the risk
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of mitochondrial disease is mitochondrial donation (also known
as mitochondrial replacement therapy). The novel IVF treatment
involves transferring the mother’s nDNA from an affected egg
into an enucleated egg from an unaffected donor, resulting in an
embryo containing nDNA from both parents but mostly wild-
type mtDNA from the healthy donor and a much lower risk of
mitochondrial disease. The technique can be performed either
before or after fertilization. Before fertilization, maternal spindle
transfer (MST) or polar body transfer (PBT) can be used, while
in fertilized eggs pronuclear transfer (PNT) can be used [71, 72].
Preclinical research studies have been important in confirming
the potential of these techniques to reduce the risk of mitochon-
drial disease [73–75] and addressing the safety and efficacy of
mitochondrial donation before clinical implementation [76].
Mitochondrial donation was approved for clinical use in the
UK following an extensive policy process that led to the mito-
chondrial donation regulations being passed into law in
March 2015 [77]. This legislative change allows the Human
Fertilisation and Embryology Authority (HFEA) to issue li-
cences to fertility centers who want to offer mitochondrial dona-
tion as a novel IVF treatment to reduce the risk of mitochondrial
disease. To ensure strict regulation, license applications must be
approved on a case-by-case basis for every patient and will only
be consideredwhen certain criteria are fulfilled as outlined by the
HFEA. As this option is only applicable for mitochondrial dis-
eases caused by mtDNA mutations, it could potentially benefit
approximately 150 women each year in the UK [78].
Concluding Remarks
Mitochondrial myopathies are progressive myopathies caused
by the impairment of oxidative phosphorylation (OXPHOS).
Alongside the traditional histochemical, immunohistochemi-
cal, and biochemical assays, the diagnosis of mitochondrial
myopathies has been revolutionized by the introduction of
NGS. NGS allows for a high-throughput screening of
mtDNA and nDNA. However, there are currently no effective
or disease-modifying treatments available for mitochondrial
myopathies to halt the progression of the disease. Instead,
existing therapeutic options have been focusing on the symp-
tomatic management of disease manifestations. The develop-
ment of large cohorts of patients with mitochondrial disease is
enabling extensive studies to investigate the therapeutic ef-
fects of a variety of compounds shown to be of potential value
in animal models. New molecular strategies, namely mtZFNs
and mtTALENs, that cause beneficial heteroplasmic shifts in
cell lines harboring varying pathogenic mtDNA mutations
offer hope for the future. Moreover, recent developments in
the reproductive options for patients with mitochondrial my-
opathies mean that for most families, the possibility of
preventing transmission of the mutation to the next generation
is now possible.
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